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L E T T E R TO TH E ED I TOR
Coronavirus uses as binding site in humans
angiotensin‐converting enzyme 2 functional receptor that
is involved in arterial blood pressure control and fibrotic
response to damage and is a drug target in cardiovascular
disease. Is this just a phylogenetic coincidence?
To the Editor,
I read with great interest the paper published ahead‐of‐print in the
Journal of Medical Virology by Liu et al1 on comparisons of the spike
sequences between severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) and SARS‐CoV, bat SARS‐like CoV, and other cor-
onaviruses, supporting the fact that snakes, pangolins, also turtles may
act as potential intermediate hosts that transmit SARS‐CoV‐2 to hu-
mans. As we do believe that the evolutionary analysis and finding on the
possible virus reservoirs are helpful in understanding the diffusion of
the novel 2019 coronavirus (SARS‐CoV‐2) causing the coronavirus
disease (COVID‐19), with this letter I want to discuss the implications
that descend from the coincidence of the virus binding site with the
membrane angiotensin‐converting enzyme 2 (ACE2) receptor.2
As it was previously stated, for the establishment of SARS cor-
onavirus infections, the endocytosis of virus particles into host cells is
needed. Surprisingly, the ACE2 has been identified as a functional re-
ceptor,3 as ACE2–Spike interaction is the mechanisms that lead through
a process of internalization with ACE2, to the endocytosis4 (Figure 1).
This mechanism is shared with all SARS coronavirus family that, now,
includes the SARS‐CoV‐2 causing the severe COVID‐19.
According to the cardiologists, ACE, which belongs to the
renin–angiotensin–aldosterone system (RAAS), is involved, at multi-
ple levels, in blood pressure control and, for example, myocardial
fibrotic response to damage5; since the discovery of the first ACE
inhibitor (ACEi), remarkably found in the peptides from the venom of
the snake Bothrops jararaca,6 it has become a main component for the
treatment of high blood pressure and heart failure.7 Furthermore, it
should be underlined that ACE2 is a homolog of ACE that was
identified in the 2000s8; indeed, we do have (at least) two ACE re-
ceptors, AT1 and AT2. We do have much more information on ACE1
effects, whereas details about ACE2 is only assumed; cardiovascular
therapies are focused on ACE1, although ACE2 is supposed to be a
promising target. We know also that ACE2 is abundantly present in
the epithelia of the human lungs, which might explain the possible
routes of the COVID‐19 providing evidence to the recently observed
severe case of pneumonia in China with a high mortality rate, and in
the intestine, suggesting other possible routes of transmission.9
Thus, the questions that I want to point out and discuss with
virologists are as follows:
1. How is common to share biomolecular targets between viruses
and active mediators of the cardiovascular system? Is it a “coin-
cidence” due to the spread over species and ancient phylogeny of
renin–angiotensin system? I mean, do viruses use as a binding site
a functional receptor that is, usually, involved in the control of
vascular tone, arterial blood pressure, and fibrotic response to
damage? Is this functional? Or, instead, if this is not common, it is
a possible evolution of viruses, eventually, driven by experiments
and/or worldwide use of treatment targeting RAAS receptors?
2. This fact raises questions on safety when using ACEi and angio-
tensin receptor blockers (ARBs) in patients affected by COVID‐
19, as these therapies, which are widely used for the treatment of
high blood pressure and heart failure, having as main target ACE1,
can cause the upregulation of ACE2, with the consequence of
open access routes to the COVID‐19. On the contrary, it is not
possible to exclude that less‐selective ACEi/ARBs might be also
helpful by blocking, even partially, ACE2. In this regard, it might
be useful to obtain epidemiological data on patients affected by
COVID‐19 that are assuming ACEi/ARB.
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F IGURE 1 Internalisation of SARS‐CoV into an epithelial cell by
using ACE2 as functional receptor. ACE1, angiotensin‐converting‐
enzyme 1; ACE2, angiotensin‐converting‐enzyme 2; ANG I,
angiotensin I; ANG II, angiotensin II; ANG 1–7, angiotensin from 1 to
7; AT1r, angiotensin receptor 1; AT2r, angiotensin receptor 2
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